

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Perricaudet et al.

Group Art Unit: 1804

Serial No.: 08/397,225

Examiner: S. Ziska

International Filing Date: 08 July 1994

For: Defective Adenovirus Vectors And Use Thereof In Gene Therapy

To: The Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231TO: Examiner S. Ziska
Facsimile No.: (703) 308-0294
THE COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Paula L. Dickey

(Type or print name of person signing certification)

Date: Oct 10, 1997Paula L. Dickey

(Signature of person signing certification)

RECEIVED
OCT 10 1997
GROUP 1800

FEE FOR CLAIMS

Transmitted herewith is an amendment in the above-identified patent application. The fee for claims (37 CFR 1.16(b)-(d)) has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	Other Than A Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fee
Total	35	Minus	31	= 4	x 22 =	\$ 88.00
Indep	4	Minus	4	= 0	x 82 =	\$ 0.00
First Presentation of Multiple Dependent Claim					+ 270 =	\$
					TOTAL	\$ 88.00

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS CASE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS CASE is less than 3, write "3" in this space.

RPR File No. EX93015G1-US

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

 No additional fee is required.

 X Please charge my Deposit Account No. 18-1982 in the amount of \$88.00.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or fees during the pendency of this application which may be required or credit any overpayment to the above Deposit Account:

Any filing fees required under 37 CFR 1.16; any patent application processing fees under 37 CFR 1.17; and/or any filing fees under 37 CFR 1.16 for presentation of extra claims.

A triplicate copy of this sheet is enclosed.

Respectfully submitted,



Paul F. Fehlner, Ph.D.
Attorney for Applicants
Registration No. 35,135

Dated: 10/10/97

Rhône-Poulenc Rorer, Inc.
Mail Drop 3C43
P.O. Box 5093
Collegeville, PA 19426-0997
Telephone: (610) 454-3839
Facsimile: (610) 454-3808

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Perricaudet, et al.
Serial No.: 08/397,225
International Filing Date: 08 July 1994

Group Art Unit: 1804
Examiner: A. Milne

For: DEFECTIVE ADENOVIRUS VECTORS AND USE THEREOF IN GENE
THERAPY

To: Assistant Commissioner of Patents
Washington, D.C. 20231

TO: Examiner A. Milne
Facsimile No.: (703) 308-0294
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed)
is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Date: Oct 10, 1997

Paula L. Dickey
(Type or print name of person signing certification)

Paula L. Dickey
(Signature of person signing certification)

SUPPLEMENTAL AMENDMENT UNDER 37 CFR §1.115

Further to Applicants' amendment filed July 11, 1997, and in accordance
with Rule 115 of the Rules of Practice, please consider the following
amendments and remarks.

AMENDMENT

IN THE CLAIMS

Please amend the claims as follows:

- E
1. (Four Times Amended) A defective recombinant adenovirus
comprising
ITR sequences,
an encapsulation sequence, and
a heterologous DNA sequence,
- Sub
Oct